Madrid

• Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy … Pending
  2025-523010-89-00 3 Pulmonary arterial hypertension
• A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0 … Pending
  2025-523058-16-00 4 Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhib
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In … Pending
  2025-523087-20-00 5 Duchenne muscular dystrophy
• A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o … Pending
  2025-523117-28-00 4 Relapsed or Refractory Multiple Myeloma
• STUDY TO FIND OUT WHETHER A SHORTER ANTIBIOTIC TREATMENT (7 DAYS) IS AS EFFECTIVE AND SAFE AS THE USUAL ONE (14 DAYS) IN PATIENTS WITH AN IN … Pending
  2025-523120-53-00 11 Graft pyelonephritis in kidney transplant recipients
• A study to learn if fenfluramine hydrochloride is safe and works in people with Rett syndrome Pending
  2025-523157-34-00 5 Rett syndrome
• Pralsetinib (Gavreto) drug drug interaction study in patients with RET+ advanced or metastatic solid tumors. Pending
  2025-523158-15-00 11 Patients with advanced or metastatic solid tumors
• A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia … Pending
  2025-523238-17-00 4 Acute myeloid leukemia
• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer Pending
  2025-523276-23-00 7 Extensive stage small cell lung cancer
• An Open-label, Rollover Study to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease Pending
  2025-523280-38-00 4 Thyroid Eye Disease
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5 Relapsed or Refractory Multiple Myeloma
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS Pending
  2025-523396-38-00 9 Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r high
• A First-In-Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination with Cemiplimab Works in Adult Participan … Pending
  2025-523399-22-00 7 Melanoma
• Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis Pending
  2025-523400-72-00 4 Cystic fibrosis
• PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending
  2025-523425-17-00 4 Proteinuric kidney diseases
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Pending
  2025-523461-17-01 5 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Pending
  2025-523474-16-00 7 Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mu
• A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant … Pending
  2025-523481-24-00 5 Participants with Progressive Supranuclear Palsy Richardson Syndrome (
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 5 Obesity
• A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE) Pending
  2025-523488-39-00 4 Systemic lupus erythematosus
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending
  2025-523495-23-00 5 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity

Showing 193–216 of 3,550 trials